| Literature DB >> 27376092 |
Rugmani Padmanabhan Iyer1, Mira Jung1, Merry L Lindsey2.
Abstract
Following myocardial infarction (MI), the left ventricle (LV) undergoes a series of molecular, cellular, and functional alterations that are both part of the wound healing response to form a scar in the infarct region and the consequence of that response. Using the laws of thermodynamics as an analogy, we present here three laws for categorizing the post-MI LV remodeling process. The first law is that the LV will attempt to maintain equilibrium and compensate as a way to maximize function, the second law is that remodeling is progressive and unidirectional, and the third law is that the final goal is (ideally, but not always achievable) a stable, equilibrated scar. This comparison helps to define the boundaries of the system, whether it be the infarct zone, the LV, the heart, or the entire body. This review provides an overview for those not directly in the field and establishes a framework to help prioritize future research directions.Entities:
Keywords: MMP; extracellular matrix; fibrosis; inflammation; left ventricle; proteomics; remodeling
Year: 2015 PMID: 27376092 PMCID: PMC4930103 DOI: 10.2147/MNM.S74093
Source DB: PubMed Journal: Metalloproteinases Med ISSN: 2324-2027
Figure 1Remodeling of the left ventricle following myocardial infarction is the product of the inflammatory response and turnover of the extracellular matrix to remove necrotic myocytes and generate an infarct scar.
Abbreviations: Lv, left ventricle; eCM, extracellular matrix.
MMP Interventions that improve post-MI outcomes
| Intervention | Model | Time post-MI effect observed | Effect |
|---|---|---|---|
| Broad-spectrum MMP inhibitor | Mouse | 4 days | ↓ LV dilation, ↑ neovascularization |
| (CP-471 and CP-474)[ | Rabbit | 4 weeks | |
| Broad-spectrum MMP inhibitor (PD166793)[ | Pig | 5 days | ↓ MI size and expansion |
| Broad-spectrum MMP inhibitor (PGE-530742)[ | Pig | 10 days | ↓ LV end-diastolic volume |
| Broad-spectrum MMP inhibitor (TISAM)[ | Mouse | 3 days | ↑ Survival, ↓ rupture |
| MMP-9 null[ | Mouse | Up to 15 days | ↓ LV enlargement, collagen accumulation |
| Macrophage-specifc MMP-9 Tg[ | Mouse | 5 days | ↑ LV function, ↓ inflammation |
| Sitaxsentan[ | Rat | 3 days | ↓ LV dilation |
| Doxycycline[ | Human | 24 hours post-MI up to 9 days | ↓ Endothelial dysfunction and ↓ |
| Angiotensin-converting enzyme inhibitors[ | Human | Up to 30 days | ↓ MMP-1 levels and collagenolytic activity |
| TIMP null[ | Mouse | Up to 14 days | ↑ LV remodeling |
Abbreviations: ↓, decreased; ↑, increased; Lv, left ventricle; MI, myocardial infarction; MMP, matrix metalloproteinase; Tg, transgenic; TIMP, tissue inhibitor of metalloproteinase; TISAM, 2R-2-[5-[4-[ethyl-methylamino]phenyl]thiophene-2-sulfonylamino]-3-methylbutyric acid.
Examples of applying the laws of MI thermodynamics to post-MI inflammation and extracellular matrix responses following matrix metalloproteinase-9 modulation
| Law | Example | Insights gained |
|---|---|---|
| First: post-MI, the cardiac system remodels in | MMP-9 deletion limits early inflammation to reduce | Early inflammation and ECM |
| Second: post-MI, the LV undergoes unidirectional | Macrophage-specific MMP-9 overexpression blunts pro- | Cell-to-cell communication and |
| Third: post-MI, the infarct approaches scar | While day 28 post-MI inflammation in the infarct is | End scar quality and LV function is |
Note: Data from references.[22,28–32]
Abbreviations: MI, myocardial infarction; LV, left ventricle; MMP-9, matrix metalloproteinase-9; ECM, extracellular matrix.
MMP interventions that worsen post-MI outcomes
| Intervention | Model | Time post-MI effect observed | Effect |
|---|---|---|---|
| RXP 470.1 (MMP-12i)[ | Mouse | Days 1–7 | ↑ LV dilation, ↑ inflammation |
| MT1-MMP Tg[ | Mouse | Up to 14 days | ↑ LV remodeling, fbrosis, ↓ survival |
| MMP-28 null[ | Mouse | Up to 28 days | ↑ LV dysfunction and rupture |
Abbreviations: ↓, decreased; ↑, increased; MMP, matrix metalloproteinase; MI, myocardial infarction; Lv, left ventricle; MT, membrane type; Tg, transgenic.